Vidula, Neelima http://orcid.org/0000-0002-5963-7052
Lipman, Andrew
Kato, Shumei
Weipert, Caroline
Hesler, Katherine
Azzi, Georges
Elkhanany, Ahmed http://orcid.org/0000-0001-7681-6872
Juric, Dejan http://orcid.org/0000-0003-2983-7704
Rodriguez, Estelamari
Faulkner, Colleen
Makhlouf, Paul
Price, Kristin
O’Shaughnessy, Joyce
Bardia, Aditya
Article History
Received: 3 May 2022
Accepted: 21 October 2022
First Online: 4 November 2022
Competing interests
: Individual disclosures for co-authors are as noted below: A.L.: The author declares no competing financial and non-financial interests. S.K.: The author declares no competing financial and non-financial interests. K.H.: The author declares no competing financial and non-financial interests. A.E.: The author declares no competing financial and non-financial interests. E.R.: The author declares no competing financial and non-financial interests. CF: The author declares no competing financial and non-financial interests. P.M.: The author declares no competing financial and non-financial interests. N.V.: The author declares no competing non-financial interests but the following competing financial interests: Research funding to the institution (Massachusetts General Hospital): Merck, Daehwa, Pfizer, Radius, and Novartis; Advisory board participation (single session): AbbVie, OncoSec, Aadi, Gilead. D.J.: The author declares no competing non-financial interests but the following competing financial interests: Consulting fees from Novartis, Genentech, Syros, Eisai, Vibliome, Mapkure, and Relay Therapeutics. Contracted research with Novartis, Genentech, Syros, Pfizer, Eisai, Takeda, Ribon Therapeutics, Infinity, InventisBio, Cyteir, Blueprint Medicines, and Arvinas. Ownership interest in Relay Therapeutics and PIC Therapeutics. C.W.: The author declares no competing non-financial interests but the following competing financial interests: Employee and stockholder of Guardant Health. G.A.: The author declares no competing non-financial interests but the following competing financial interests: Speaker bureau for Guardant Health and Natera. K.P.: The author declares no competing non-financial interests but the following competing financial interests: Employee and stockholder of Guardant Health JS: The author declares no competing non-financial interests but the following competing financial interests: Honoria for consulting and/or advisory board: AbbVie Inc., Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Carrick Therapeutics, Celgene Corporation, Clovis Oncology, Daiichi Sankyo, Eisai, GI Therapeutics, Genentech, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Takeda, Synthon. A.B.: The author declares no competing non-financial interests but the following competing financial interests: Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/AstraZeneca, Phillips, Eli Lilly, Foundation Medicine. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/AstraZeneca, Eli Lilly.